Featured Research

from universities, journals, and other organizations

Vaccine Improves Event-free Survival For Leukemia Patients

Date:
December 11, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than nonresponders, according to researchers.

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Immune response to the PR1 vaccine was associated with an 8.7 month event-free survival compared with 2.4 months for non-responders. Clinical responses ranging from improvements in blood counts to complete cytogenetic remission were observed in 36 percent of the responders compared with 10 percent of non-responders.

"We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival" says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy.

The Phase I/II clinical trial that ran from 2000 to 2006 was designed to assess the vaccine's safety and its ability to elicit an immune response. Toxicity was limited to low-grade injection site side effects such as redness, swelling and some pain.

The PR1 vaccine is derived from two myeloid leukemia-associated antigens, proteins that are either overexpressed or aberrantly expressed in cancer cells. When PR1 elicits an immune response, PR1-specific cytotoxic T lymphocytes are produced that selectively kill three types of leukemia - myelodysplastic syndrome, acute myelogenous leukemia and chronic myelogenous leukemia.

Out of 66 patients in the trial, 53 had active disease and 13 were in remission when they entered the trial. Of the 53 with one of the three types of active leukemia, 25 (47 percent) had an immune response and 28 did not. Nine out of 25 responders (36 percent) had some type of clinical response compared with three of the 28 non-responders (10 percent).

Among the 13 in remission at the start of the trial, four remained in remission for a median time of 30.5 months.

In phase I trials, patients have been heavily pretreated with other therapies. "We had good accrual and a reasonably long follow-up of almost three years," Qazilbash says, "For a Phase I/II, that's a fair number of patients."

"Immunotherapy works best for low level of disease," Qazilbash says. "So patients with low leukemia burden may get the maximum benefit."

Disease-specific Phase II clinical trials of the vaccine for chronic myelogenous leukemia and myelodysplastic syndrome are planned or under way at M. D. Anderson. The Vaccine Company, which makes the PR1 vaccine, is conducting a national Phase III clinical trial for acute myelogenous leukemia.

Co-authors with Qazilbash and Molldrem are Eric D. Weider, Ph.D., Rosa L. Rios, Sijie Lu, Ph.D., Shreya Kant, Sergio Giralt, M.D., Krishna Komanduri, M.D., and Richard Champlin, M.D., all of the Department of Stem Cell Transplantation and Cellular Therapy; Peter F. Thall, Ph.D., and Xuemei Wang, of M. D. Anderson's Department of Biostatistics; and Elihu H. Estey, M.D., of Jorge Cortes, M.D., M. D. Anderson's Department of Leukemia.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Vaccine Improves Event-free Survival For Leukemia Patients." ScienceDaily. ScienceDaily, 11 December 2007. <www.sciencedaily.com/releases/2007/12/071210094351.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, December 11). Vaccine Improves Event-free Survival For Leukemia Patients. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2007/12/071210094351.htm
University of Texas M. D. Anderson Cancer Center. "Vaccine Improves Event-free Survival For Leukemia Patients." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210094351.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins